معرفی
Roy Drissen is a Postdoctoral Researcher at the Weatherall Institute of Molecular Medicine (University of Oxford) working within the Hematopoietic Stem Cell Genetics department under the Nerlov Group. He holds a PhD from Erasmus MC in Rotterdam and has held postdoctoral positions at the WIMM (2005–2009) and the Centre for Regenerative Medicine in Edinburgh (2009–2012), before returning to the WIMM.
- PhD: Erasmus MC, Rotterdam (1999–2005)
- Postdoc: WIMM (2005–2009)
- Postdoc: Centre for Regenerative Medicine, Edinburgh (2009–2012)
- Current: WIMM (University of Oxford)
Drissen investigates hematopoietic stem cell (HSC) lineage commitment and myeloid cell differentiation using single-cell technologies. His work has revealed dual pathways in myeloid development, particularly focusing on eosinophils, basophils, and mast cells, with implications for myeloid malignancies like systemic mastocytosis. He combines mouse and human models to study normal and malignant hematopoiesis, emphasizing transcription factor regulation and epigenetic programming.
His recent publications highlight epigenetic mechanisms in HSC fate restriction (2023), enhancer-driven oncogene synergy in CEBPA/CSF3R mutant AML (2019), and identification of distinct myeloid pathways (2016). His research spans from basic erythroid gene regulation to malignant transformation models, reflecting a trajectory from transcriptional control to cancer biology.
